Finance

Lists
AKUMS:NSE
Akums Drugs and Pharmaceuticals Ltd
₹776,00
+0,87%
(+6,70) 1D
14 Okt., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AKUMS...
Open
₹773,95
High
₹776,00
Low
₹753,30
Mkt. cap
118,81 mjd
Avg. vol.
291,87 k
Volume
134,29 k
Dividend
0,13%
Quarterly dividend
₹0,25
Ex-dividend date
03 Jul. 2026
P/E ratio
40,74
52-wk high
₹838,80
52-wk low
₹409,30
EPS
₹19,05
No. of employees
7 k
Open
₹773,95
High
₹776,00
Low
₹753,30
Mkt. cap
118,81 mjd
Avg. vol.
291,87 k
Volume
134,29 k
Dividend
0,13%
Quarterly dividend
₹0,25
Ex-dividend date
03 Jul. 2026
P/E ratio
40,74
52-wk high
₹838,80
52-wk low
₹409,30
EPS
₹19,05
No. of employees
7 k
News stories
From web sources and news partners
Profile
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024. Wikipedia
About Akums Drugs and Pharmaceuticals Ltd
CEO-
Employees7,34 k
Founded2004
Headquarters-
SectorHealth care
Websiteakums.in
Last report
10 Aug. 2026
Fiscal period
Q1 2027
₹6,53 / ₹6,10
+7,05%beat
Revenue / Est. (INR)
11,67 mjd / 11,65 mjd
+0,14%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
10,18 mjd
11,60 mjd
11,60 mjd
11,67 mjd
Cost of goods sold
5,93 mjd
6,79 mjd
7,37 mjd
6,45 mjd
Cost of revenue
5,93 mjd
6,79 mjd
7,37 mjd
6,45 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 mjd
1,89 mjd
2,37 mjd
2,01 mjd
Operating expense
3,68 mjd
3,74 mjd
3,09 mjd
3,88 mjd
Total operating expenses
9,61 mjd
10,52 mjd
10,46 mjd
10,33 mjd
Operating income
566,12 m
1,07 mjd
1,14 mjd
1,34 mjd
Other non operating income
323,65 m
343,28 m
-942,12 m
303,80 m
EBT including unusual items
656,73 m
995,66 m
1,21 mjd
1,39 mjd
EBT excluding unusual items
656,73 m
1,18 mjd
1,19 mjd
1,39 mjd
Income tax expense
229,77 m
318,92 m
398,74 m
382,59 m
Effective tax rate
34,99%
32,03%
32,89%
27,48%
Other operating expenses
1,41 mjd
1,45 mjd
319,86 m
1,45 mjd
Net income
407,83 m
663,17 m
846,13 m
1,00 mjd
Net profit margin
4,01%
5,72%
7,29%
8,57%
Earnings per share
2,66
5,14
-
6,53
Interest and investment income
-
-
1,10 mjd
-
Interest expense
-233,04 m
-237,42 m
-184,41 m
-247,56 m
Net interest expenses
-233,04 m
-237,42 m
912,36 m
-247,56 m
Depreciation and amortization charges
378,64 m
396,49 m
401,18 m
410,65 m
EBITDA
940,04 m
1,42 mjd
1,49 mjd
1,69 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme